Prolacta Raises $12 Million

Prolacta Bioscience, a Monrovia, Calif.-based developer of a human milk fortifier for infants neonatal intensive care units, has raised $12 million in Series C funding. Alta Partners led the deal, and was joined by DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund and Draper Associates. In other Prolacta news, the company named former Baxter Bioscience president John Bacich as board chairman.